Employees: 384
Size Star Sports Medicine (1609.HK) is a Hong Kong Health Care company (Medical Specialties) with a market value of $364M, the 836th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$53.45 on 18 Nov 2026.
Performance Over six months the shares fell 72.8%, against -14.4% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — lowest of 20 in its peer set.
Growth Revenue grew 23.1% over the last twelve months (peer median +7.1%); the operating margin is 37.2% (peer median 9.4%).
Valuation It trades at 3.7× enterprise value to sales against a peer median of 1.8× (10th most expensive of 21).
Price implies For today's price to make sense, revenue must grow about -13% a year for seven years (Req g). Recent delivered growth is +37%, so the hurdle is -50 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 49.7 points above its cost of capital (5.9% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | n/a | HK$437M | HK$355M | HK$264M | HK$170M |
| Revenue growth | — | +23% | +35% | +55% | — |
| Gross profit | n/a | HK$320M | HK$241M | HK$191M | HK$118M |
| EBITDA | n/a | HK$179M | HK$126M | HK$76.6M | HK$48.4M |
| Net income | n/a | HK$149M | HK$103M | HK$63.1M | HK$46.9M |
| Free cash flow | n/a | HK$135M | HK$73.0M | HK$64.8M | HK$56.8M |
| Capital expenditure | n/a | HK$37.1M | HK$29.4M | HK$23.5M | HK$9.90M |
| Total debt | n/a | HK$36.3M | HK$24.0M | HK$9.17M | HK$12.4M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 1609.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -10.4% | -12.0% | 10th highest of 21 |
| 6-month return | -72.8% | -14.4% | lowest of 20 |
| Distance from 52-week high | -82.1% | -43.6% | lowest of 21 |
| Revenue growth (TTM) | +23.1% | +7.1% | 4th highest of 21 |
| Operating margin | 37.2% | 9.4% | highest of 21 |
| EV / Sales | 3.7× | 1.8× | 10th most expensive of 21 |
| Growth the price implies (Req g, 7 yrs) | -13.1% | -2.3% | 3rd least demanding of 15 |
| Growth delivered (Del g) | +36.8% | +3.9% | 2nd highest of 15 |
| Hurdle (Req g minus delivered) | -50.0 pp | -0.3 pp | 2nd least demanding of 15 |
| ROIC minus cost of capital | +49.7 pp | +7.0 pp | highest of 19 |
| EV / EBITDA | 8.9× | 10.2× | 7th cheapest of 13 |
| Net debt / EBITDA | -7.1× | -1.2× | 2nd least indebted of 13 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Star Sports Medicine 1609.HK | Hong Kong | $364M | -73% | +23% | 37% | 3.7× | -13.1% | +36.8% |
| Stratec SBS.DE | Germany | $365M | +63% | -6% | 4% | 1.8× | 19.1% | +0.1% |
| CapsoVision CV | United States | $366M | +5% | +15% | -213% | 24.8× | n/a | n/a |
| Beijing Succeeder Technology 688338.SS | China | $362M | -18% | -4% | 31% | 4.2× | 5.7% | +3.4% |
| Brainsway Ltd Sponsored ADR BWAY | United States | $373M | -41% | +32% | 14% | 4.8× | 24.9% | +18.8% |
| Guangdong Transtek Medical Electronics 300562.SZ | China | $373M | -15% | +7% | 11% | 1.8× | -4.2% | -6.0% |
| Yantai Zhenghai Bio-Tech 300653.SZ | China | $354M | -23% | -8% | 17% | 5.4× | 18.4% | +4.4% |
| ACRO Biomedical 6748.TWO | Taiwan | $377M | +158% | +45% | -178% | 218.3× | n/a | n/a |
| IVF HARTMANN VBSN.SW | Switzerland | $352M | -2% | +7% | 14% | 1.1× | -12.7% | -1.3% |
| Medcaptain Medical Technology 2041.HK | Hong Kong | $378M | n/a | +19% | 2% | 1.5× | 17.1% | +18.1% |
| Shanghai General Healthy Information & Technology 605186.SS | China | $379M | -26% | -11% | 5% | 7.8× | n/a | n/a |
| InBody 041830.KS | South Korea | $380M | -13% | +22% | 22% | 1.4× | -10.3% | +16.9% |
| Embecta EMBC | United States | $345M | +99% | -8% | 26% | 1.6× | -19.9% | -0.1% |
| YD Bio YDES | United States | $344M | +7% | +17% | -883% | 571.2× | n/a | n/a |
| Taidoc Technology 4736.TW | Taiwan | $387M | 0% | 0% | 19% | 1.8× | -9.5% | -6.6% |
| Shanghai Kehua Bio-Engineering 002022.SZ | China | $389M | -14% | +7% | -40% | 1.7× | n/a | n/a |
| Cerus CERS | United States | $392M | -28% | +14% | -12% | 1.8× | n/a | n/a |
| SEERS 458870.KS | South Korea | $392M | -70% | +174% | 37% | 5.5× | -6.3% | +247.0% |
| COLTENE CLTN.SW | Switzerland | $339M | -7% | -2% | 8% | 1.4× | -0.3% | -0.7% |
| Nanjing Medlander Medical Technology 688273.SS | China | $337M | -47% | -12% | 8% | 4.2× | 35.3% | +5.2% |
| OrbusNeich Medical 6929.HK | Hong Kong | $394M | -15% | +16% | 23% | 1.0× | -17.6% | +15.4% |